SCHEMBL30296102

SCHEMBL30296102

COC(=O)Cc1cc(F)ccc1OC

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.52
HSD17B10 Q99714 1/20 0.50
ALDH1A1 P00352 4/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 2/20 0.46
CYP3A4 P08684 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
CSNK1D P48730 1/20 0.44
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
POLB P06746 2/20 0.43
MAPT P10636 2/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
FFAR1 O14842 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23362766 1.00 SMN1; SMN2 (0.52) SMN1; SMN2HSD17B10ALDH1A1GAAHPGD
SCHEMBL3144672 0.88 SMN1; SMN2 (0.51) SMN1; SMN2CYP3A4CYP1A2CYP2C19CSNK1D
SCHEMBL30296208 0.86 ALDH1A1 (0.41) SMN1; SMN2HSD17B10ALDH1A1GAAHPGD
SCHEMBL23362831 0.86 ALDH1A1 (0.41) SMN1; SMN2HSD17B10ALDH1A1GAAHPGD
SCHEMBL6343901 0.85 DPP4 (0.47) SMN1; SMN2HSD17B10ALDH1A1GAAHPGD
SCHEMBL6343545 0.84 HSD17B10 (0.70) SMN1; SMN2HSD17B10ALDH1A1GAAMEN1
SCHEMBL29431167 0.84 HSD17B10 (0.70) SMN1; SMN2HSD17B10ALDH1A1GAAMEN1
SCHEMBL8063678 0.84 MAPK8 (0.46) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL10864128 0.84 CYP3A4 (0.62) SMN1; SMN2HSD17B10ALDH1A1GAAHPGD
SCHEMBL24713929 0.83 SMN1; SMN2 (0.57) SMN1; SMN2HSD17B10ALDH1A1GAACSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115811977-A Allosteric EGFR inhibitors and methods of use thereof 达纳-法伯癌症研究所股份有限公司 2023-03-17 CN disclosed